|Mr. Barton P. Bandy||Pres, CEO & Director||N/A||N/A||1961|
|Dr. Mark B. Knudson||Co-Founder and Special Advisor to the CEO||N/A||N/A||1949|
|Dr. Katherine S. Tweden Ph.D.||Co-Founder||N/A||N/A||1961|
|Mr. Thomas Stankovich||Chief Financial Officer||N/A||N/A||1961|
|Mr. Vipul Shah||Sr. VP of Operations and R&D||N/A||N/A||N/A|
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
ReShape Lifesciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.